The Early Detection Research Network: 10-year outlook

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 60-67

  Srivastava, Sudhir ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DNA;

BIOINFORMATICS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CONSENSUS DEVELOPMENT; EARLY DIAGNOSIS; HUMAN; SERUM; SHORT SURVEY; SPUTUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; URINE;

EARLY DIAGNOSIS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872032987     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.184697     Document Type: Short Survey

References (13)

1. Wagner PD, Srivastava S. New paradigms in translational science research in cancer biomarkers. Transl Res 2012;159:343-53.
2. Crichton DJ, Mattman CA, Tornquist IM, Anton K, Hughes JS. Bioinformatics: biomarkers of early detection. Cancer Biomark 2010;9:511-30.
3. NCI. The Early Detection Research Network. November 2011, 5th report, NIH publication number 10-7696. http://edrn.nci.nih.gov/docs (Accessed March 2012).
4. NCI. EDRN initial report: translational research to identify early cancer and cancer risk, October 2000, publication number 01-4852. http://edrn.nci.nih. gov/docs (Accessed March 2012).
5. Pepe MS, Feng Z, Janes H, Bossuyt, PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432- 8.
6. NIH. Announcement of the NCI Early Detection Research Network (EDRN) Program for Rapid, Independent Diagnostic Evaluation (PRIDE) for cancer biomarkers. http://grants.nih.gov/grants/guide/notice-files/NOT-CA-07-003.html (Accessed December 2012).
7. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226-45. (Pubitemid 41192032)
8. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008;54:44-52. (Pubitemid 351182595)
9. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54:53-60. (Pubitemid 351182596)
10. Sokoll LJ, Sanda M, Feng Z, Kagan J, Mizrahi IA, Broyles DL, et al. A prospective, multicenter, NCI EDRN study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-200.
11. Daniel CW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4:365-74.
12. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011;4:375- 82.
13. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.